Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA
description
Transcript of Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA
![Page 1: Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA](https://reader034.fdocuments.net/reader034/viewer/2022051401/56814846550346895db55c2b/html5/thumbnails/1.jpg)
Improving outcome of STEMI PCI: Preliminary Results of Crystal AMI
trial
Rajesh M. Dave, MDPrincipal investigator on behalf of Crystal
AMI InvestigatorsHarrisburg, PA
![Page 2: Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA](https://reader034.fdocuments.net/reader034/viewer/2022051401/56814846550346895db55c2b/html5/thumbnails/2.jpg)
DisclosureAtrium Medical: Consultant, Research
support, Training and speaking HonorariumEli Lilly: Speaker Honorariums
![Page 3: Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA](https://reader034.fdocuments.net/reader034/viewer/2022051401/56814846550346895db55c2b/html5/thumbnails/3.jpg)
BackgroundDistal embolization of atherothrombotic material remains a
significant challenge during STEMI PCI
Consequences: No Reflow, Poor TIMI and MBG grade, Higher MACE, Late ST if DES placed on thrombus
Long term mortality is higher in patients with large degree of distal embolization
Aspiration thrombectomy has shown improvement in MBG grades, however, it is not universally effective
Hence, new modalities to address thrombus burden are investigated
Many studies have demonstrated benefit of IC Abciximab- reduce no reflow, infarct size, Improved TIMI flow and Blush Scores
![Page 4: Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA](https://reader034.fdocuments.net/reader034/viewer/2022051401/56814846550346895db55c2b/html5/thumbnails/4.jpg)
Is the myocardial blush grade scored by the operator during primary percutaneous coronary intervention of prognostic value in patients with ST elevation myocardial infarction in routine clinical practice?
One Year Mortality in Primary PCI 0 I II III
TIMI Flow: 46.3% 25% 8.4% 6.6%
Blush Scores: 24.0 9.7 5.8% 4.3%
Despite TIMI-3 Flow, Normal Blush in ONLY 45%
Myocardial Blush Grade: 0 I II III
Mortality in pts. w/TIMI-3 FlowP value: < .001
17% 10 6% 4%
Normal epicardial flow does not necessarily correlate with normal Perfusion. Microvascular dysfunction caused by embolization, likely results in impaired myocardial perfusion.Kampinga MA, Nijsten MWN, Gu YL, et al. Circ Cardiovasc Interv. 2010;3:216-223.
N= 2,118 consecutive STEMI patients
![Page 5: Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA](https://reader034.fdocuments.net/reader034/viewer/2022051401/56814846550346895db55c2b/html5/thumbnails/5.jpg)
Meta Analysis of IC Versus IV Abciximab administration of peer reviewed studies (N=2,301) 997 STEMI, 1304 NSTEMI
Hansen et al. Journal of Invasive Cardiology Vol 22; 6. June 2010. 278-282.
![Page 6: Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA](https://reader034.fdocuments.net/reader034/viewer/2022051401/56814846550346895db55c2b/html5/thumbnails/6.jpg)
IC Abciximab delivery with ClearWay™Therapeutic Drug Delivery Balloon: Concept
ClearWay™ Drug Delivery Balloon: Allows super-selective IC delivery of Abciximab in higher concentration versus IV
Superiority to Guide catheter Abciximab delivery: Prevents loss of drug in aorta, no wire exchange needed
Higher residence time of drug allows expression of disaggregating and anti-inflammatory properties of Abciximab 1
Hypothesis: Delivery of IC Abciximab with ClearWay™ leads to better ST resolution, higher MBG, Improved TIMI flow and smaller Infarct size than IV Abciximab during STEMI PCI
CRYSTAL AMI: Pilot proof of concept trial, not powered to show statistical differences
1. Prati et al., COCTAIL Study, JACC, 2010.
![Page 7: Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA](https://reader034.fdocuments.net/reader034/viewer/2022051401/56814846550346895db55c2b/html5/thumbnails/7.jpg)
CRYSTAL AMI: Study DesignSingle center, prospectively randomized
IV Abciximab ClearWay™ IC Abciximab
R 1:1
PCI as per standard of care, EvaluateMBG, TIMI flow, ST Resolution, LV Function at Discharge
30 day follow up, Echo, Resting Sestamibi
STEMI within 6 hours, Heparin, 600mg Clopidogrel (n=50)
![Page 8: Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA](https://reader034.fdocuments.net/reader034/viewer/2022051401/56814846550346895db55c2b/html5/thumbnails/8.jpg)
DemographicsTreatment arm N=48
IC =25 IV=23
Male/Female M=23, F=2 M=18, F=5
Age 62 + 25 65 + 23
HTN 14 14
Angina 5 2
CHF 1 0
Prior PCI 6 2
CABG 3 1
DM 8 6
Lipids 14 9
Smoking C=9, F=2 C=6, F=0
![Page 9: Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA](https://reader034.fdocuments.net/reader034/viewer/2022051401/56814846550346895db55c2b/html5/thumbnails/9.jpg)
Manual/Mechanical Extraction catheter use (discretion of operator)
(n = 25) (n = 23)
![Page 10: Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA](https://reader034.fdocuments.net/reader034/viewer/2022051401/56814846550346895db55c2b/html5/thumbnails/10.jpg)
TIMI Flow Comparison in first 48 patients
16
1
17
3 1
5
2
4
1
24
3
19
IC TIMI Pre IC TIMI Post IV TIMI Pre IV TIMI Post
3
2
1
0
82%
(n = 25) (n = 23)
TIMI Flow96%
![Page 11: Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA](https://reader034.fdocuments.net/reader034/viewer/2022051401/56814846550346895db55c2b/html5/thumbnails/11.jpg)
Primary Endpoint: TIMI Myocardial Blush Grade (MBG) >2 scores comparison in first 48 patients
17
1
18
72
3
1
5
2
8
0
18
1
12
IC Blush Pre IC Blush Post IV Blush Pre IV Blush Post
3
2
1
0
92%86%
1
(n = 25) (n = 23)
MBG
92% of IC versus 86% of IV patients
![Page 12: Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA](https://reader034.fdocuments.net/reader034/viewer/2022051401/56814846550346895db55c2b/html5/thumbnails/12.jpg)
MBG 3 and ST Resolution Rates comparison
18
12
21
18
IC Abciximab IV Abciximab
MBG 3
ST Resolution
In Tapas, MBG 3 was only achieved in 45% of patients in extraction arm (identical to IV Abciximab group), but was directly linked to 5 times increase in mortality. IC Abciximab Administration through ClearWay™ has resulted in 72% of patients leaving the lab with a blush score of 3.
(n = 25) (n = 23)
72%
80%
52%
70%
![Page 13: Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA](https://reader034.fdocuments.net/reader034/viewer/2022051401/56814846550346895db55c2b/html5/thumbnails/13.jpg)
Clinical Outcomes
IC IV
Readmissions 0 2
Death 0 1
![Page 14: Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA](https://reader034.fdocuments.net/reader034/viewer/2022051401/56814846550346895db55c2b/html5/thumbnails/14.jpg)
50yomale with Anterior STEMI
![Page 15: Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA](https://reader034.fdocuments.net/reader034/viewer/2022051401/56814846550346895db55c2b/html5/thumbnails/15.jpg)
ClearWay 1.5X20Abciximab bolus
![Page 16: Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA](https://reader034.fdocuments.net/reader034/viewer/2022051401/56814846550346895db55c2b/html5/thumbnails/16.jpg)
Flow restored after ClearWay
![Page 17: Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA](https://reader034.fdocuments.net/reader034/viewer/2022051401/56814846550346895db55c2b/html5/thumbnails/17.jpg)
Xience V StentReinsertion of ClearWay forLocalized Nipride administration
![Page 18: Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA](https://reader034.fdocuments.net/reader034/viewer/2022051401/56814846550346895db55c2b/html5/thumbnails/18.jpg)
![Page 19: Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators Harrisburg, PA](https://reader034.fdocuments.net/reader034/viewer/2022051401/56814846550346895db55c2b/html5/thumbnails/19.jpg)
Conclusions IC Abciximab super-selective delivery is safe and effective
delivered via ClearWay™ drug delivery balloon, and produced higher MBG scores (more achieved MBG 3 75% vs 45% ) and trend towards higher ST-Segment resolution (80% vs 70% ns)
• This study supports the findings of previous study such as TAPAS, where MBG of 3 was achieved in only 45% of patients receiving aspiration catheter and IV Abciximab.
• An equal number of patients received manual thrombus aspiration in each study arm (65%) suggesting a synergistic effect with IC Abciximab super- selective delivery with ClearWay™